Skip Navigation
  Search Menu
Find an Expert

 

Chien-Fu Hung, Ph.D.

Photo of Dr. Chien-Fu Hung, Ph.D.

Associate Professor of Pathology

Male

Research Interests: Gene therapies; cancer vaccines; ovarian cancer immunotherapy; cancer immunology

Background

Dr. Chien-Fu Hung is an associate professor of pathology and oncology and a professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine. He is a member of the Johns Hopkins Kimmel Cancer Center. His research focuses on the prevention and treatment of cervical and ovarian cancers.

His team is currently using an ascitogenic ovarian/peritoneal tumor model to investigate DNA vaccine strategies encoding ovarian tumor antigens identified by microarray and SAGE.

Dr. Hung earned his Ph.D. in molecular biology from the University of Illinois. He completed a fellowship in pharmacology at the University of Pennsylvania and a fellowship in pathology at the Johns Hopkins University.

He received a Young Investigator Award from the Alliance for Cancer Gene Therapy in 2004.

...read more

Titles

  • Associate Professor of Pathology
  • Associate Professor of Gynecology and Obstetrics
  • Associate Professor of Oncology

Departments / Divisions

Education

Degrees

  • Ph.D., University of Illinois (Urbana-Champaign) (Illinois) (1996)

Research & Publications

Research Summary

Cervical cancer is the second leading cause of death from cancer in women worldwide, while patients with ovarian cancer have a higher mortality rate than all other patients with gynecologic malignancies.

Dr. Hung’s research focuses primarily on developing immunotherapeutic, specifically vaccination, strategies for the prevention and treatment of cervical and ovarian cancers. His lab has developed several strategies to enhance immunologic responses against cancers. Some of these strategies involve targeting antigen into dendritic cells; targeting antigen into MHC class I and II processing pathways; enhancing intercellular spreading of antigen; and combining antigen-specific immunotherapy and antiangiogenesis.

Currently, his lab has developed an ascitogenic ovarian/peritoneal tumor model that can be used to investigate the interaction of the immune system with the establishment, progression and treatment of ovarian cancer in immunocompetent mice. Unlike models using human xenografts or human cell lines, which are limited to studies with immunocompromised mice, their model is capable of generating ascites and intraperitoneal tumor growth in immunocompetent C57BL/6 mice after intraperitoneal injection. They are presently investigating DNA vaccine strategies encoding ovarian tumor antigens identified by microarray and SAGE in this tumor model.

Selected Publications

Yang A, Peng S, Farmer E, Zeng Q, Cheng MA, Pang X, Wu TC and Hung CF. Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus. Cell Biosci. 2017; 7:46

Yang PM, Chou CJ, Tseng SH and Hung CF. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. Oncotarget. 2017; 8(28):46145-46162

Chuang YM, Pinn ML, Karakousis PC and Hung CF. Intranasal Immunization with DnaK Protein Induces Protective Mucosal Immunity against Tuberculosis in CD4-Depleted Mice. Front Cell Infect Microbiol. 2018; 8:31

Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV and Emens LA. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. Hum Gene Ther. 2018; 29(5):614-625

Mao CP, Peng S, Yang A, He L, Tsai YC, Hung CF and Wu TC. Programmed self-assembly of peptide-major histocompatibility complex for antigen-specific immune modulation. Proc Natl Acad Sci U S A. 2018; 115(17):E4032-E4040

Is this you? Edit Profile